A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.

The firms will work together to create a bispecific antibody with two anti-cancer payloads and evaluate its therapeutic potential.

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.

Platforms using natural language processing are showing promise in scanning patients' records for biomarkers and other enrollment criteria for clinical trials.

The firm will use the funding to advance ongoing clinical trials of its autologous cell therapies for solid tumors.

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.